WT-161 NEW
| Price | $36 | $52 | $81 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: WT-161 | CAS No.: 1206731-57-8 |
| Purity: 97.09% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | WT-161 |
| Description | WT161 is a potent and selective inhibitor of HDAC6 (IC50:0.40 nM). |
| Animal Research | Female NCr nu/nu mice were subcutaneously (sc) implanted with 17?-estradiol-sustained release pellets (0.18 mg, 60 day release time). Mice were inoculated sc with 5 × 10^6 MCF-7 cells suspended in 30% Matrigel. After 1 month of growth, mice with measurable tumors (> 50 mm^3) were assigned into cohorts receiving intraperitoneal WT161 daily (80 mg/kg) or into a control group receiving vehicle alone (10% DMSO, 90% PBS). Caliper measurements of the longest perpendicular tumor diameters were performed every alternate day to estimate the tumor volume, using the formula volume = ? x L x W^2. Animals were sacrificed when tumors reached 2 cm or if the mice appeared moribund. For each animal, relative tumor volume was determined by normalizing data to the baseline tumor volume for that animal at the start of treatment. Statistical significance was determined by 2-way ANOVA analysis[2]. |
| In vitro | Treatment of anti-multiple myeloma (MM) cell lines with WT161 triggers the accumulation of acetylated tubulin and cell death in MM cell lines more potently than tubacin. Additionally, WT161 in combination with BTZ induces synergistic cytotoxicity and overcomes BTZ resistance in vitro[1]. |
| In vivo | WT161 significantly inhibits in vivo MCF7 cell growth, associated with downregulation of ERα, in a murine xenograft model[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (218.08 mM) |
| Keywords | Histone deacetylases | Inhibitor | inhibit | Apoptosis | WT-161 | WT161 | WT 161 | HDAC |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Curcumin |
| Related Compound Libraries | Highly Selective Inhibitor Library | Histone Modification Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3700.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1000kg |
VIP4Y
|
Wuhan KEMI-WORKS Chemical Co., Ltd.
|
2023-09-21 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY